Evidence map›Paper›PMID 29147630›Full record

ArticleGlobal advances in health and medicine2017

Sulforaphane from Broccoli Reduces Symptoms of Autism: A Follow-up Case Series from a Randomized Double-blind Study.

Rhoda Lynch, Eileen L Diggins, Susan L Connors, Andrew W Zimmerman, Kanwaljit Singh, Hua Liu, Paul Talalay, Jed W Fahey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global advances in health and medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. NRF2, KEAP1 and GSK-3 levels in autism spectrum disorder: a case control study.International journal of developmental disabilities · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rhoda LynchDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Eileen L DigginsDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Susan L ConnorsDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Andrew W ZimmermanDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Kanwaljit SinghDepartment of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.
Hua LiuDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland.
Paul TalalayDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland.
Jed W FaheyDepartment of Pharmacology and Molecular Sciences, Johns Hopkins University, Baltimore, Maryland.ORCID 0000-0002-2129-1834
University of Massachusetts Chan Medical School · USJohns Hopkins University · USKennedy Krieger Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAutism spectrum disorder (ASD) affects 1 in 68 children, is characterized by impaired social interaction and communication as well as restricted or repetitive behaviors, and varies widely with respect to its causes and presentations. There are no validated pharmacologic treatments for the core symptoms of ASD. The social, medical, and economic burdens of ASD on families and caregivers are profound. We recently showed in a small clinical trial that sulforaphane (SF) from broccoli sprouts could significantly reduce the behavioral symptoms of ASD.

methodsAfter we completed the intervention phase of the original trial (2011-2013), many caregivers used over-the-counter dietary SF supplements in order to attempt to maintain improvements similar to those noted during the intervention. We periodically followed the progress of study participants through the summer of 2016.

resultsFamilies of 16 of the 26 subjects who received SF as part of the original study responded to requests for further information. Of these subjects, 6 did not continue taking SF supplements after the study. Nine of the 16 subjects are still taking an SF supplement and a 10th planned to. We present the edited testimonials of their caregivers in this case series.

conclusionsMany parents and caregivers articulated the positive effects of SF, both during the intervention phase and in the ensuing 3 years reported herein. These observations may contribute to understanding ASD and to treatments that may alleviate some of its symptoms. Diet- and supplement-based therapies deserve careful consideration for their potential to provide vital clinical as well as biochemical information about ASD.

Indexed as

glucoraphaninglucosinolateisothiocyanateprevention

Identifiers

PMID29147630
PMCPMC5672987
OpenAlexW2766411406

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.